1. Positioning of proteasome inhibitors in therapy of solid malignancies

   • Margot S. F. Roeten
   • Jacqueline Cloos
   • Gerrit Jansen

   Review Article Open access 28 November 2017 Pages: 227 - 243

   

2. B7-H3 in tumors: friend or foe for tumor immunity?

   • Gen Li
   • Yanchun Quan
   • Lijuan Wang

   Review Article 03 January 2018 Pages: 245 - 253

   

3. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations

   • Xiaojun Liu
   • Yingjun Jiang
   • William Plunkett

   Original Article 30 November 2017 Pages: 255 - 267

   

4. Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study

   • Tadahiko Shien
   • Hiroyoshi Doihara
   • Tadashi Ikeda

   Original Article Open access 01 December 2017 Pages: 269 - 275

   

5. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine

   • Lee Cheng Phua
   • Shixu Goh
   • Eric Chun Yong Chan

   Original Article 01 December 2017 Pages: 277 - 289

   

6. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis

   • Nina Hanke
   • Michael Teifel
   • Thorsten Lehr

   Original Article 04 December 2017 Pages: 291 - 304

   

7. Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia

   • Swantje Völler
   • Uwe Pichlmeier
   • Georg Hempel

   Original Article 05 December 2017 Pages: 305 - 314

   

8. Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis

   • Qi Jiang
   • Meizhen Xu
   • Xiaoqin Yang

   Original Article 05 December 2017 Pages: 315 - 323

   

9. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma

   • Hitesh B. Mistry
   • David Orrell
   • Raluca Eftimie

   Original Article Open access 08 December 2017 Pages: 325 - 332

   

10. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study

    • Yuki Kataoka
    • Katsuya Hirano
    • Hiroshige Yoshioka

    Original Article 11 December 2017 Pages: 333 - 337

    

11. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting

    • Ichidai Tanaka
    • Kenji Kawada
    • Yoshinori Hasegawa

    Original Article 12 December 2017 Pages: 339 - 345

    

12. Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients

    • L. K. Schoch
    • A. Asiama
    • Douglas E. Gladstone

    Original Article 13 December 2017 Pages: 347 - 354

    

13. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors

    • Emily Chan
    • E. Gabriela Chiorean
    • Herbert Hurwitz

    Original Article 13 December 2017 Pages: 355 - 364

    

14. CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

    • Xinna Zhou
    • Guoliang Qiao
    • H. Kim Lyerly

    Original Article 14 December 2017 Pages: 365 - 372

    

15. Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells

    • Olexandr Fedorchuk
    • Yaroslav Susak
    • Larysa Skivka

    Original Article 30 December 2017 Pages: 373 - 385

    

16. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)

    • Shunsuke Kagawa
    • Atsushi Muraoka
    • Toshiyoshi Fujiwara

    Original Article 30 December 2017 Pages: 387 - 392

    

17. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia

    • Sung-Yong Kim
    • Ji Hyun Park
    • Mark Hong Lee

    Original Article 02 January 2018 Pages: 393 - 398

    

18. Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic

    • Motoaki Ishikawa
    • Michiyasu Kawai
    • Yoshiyuki Kagawa

    Original Article 03 January 2018 Pages: 399 - 411

    

19. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer

    • Grant R. Williams
    • Allison M. Deal
    • Hanna K. Sanoff

    Short Communication 20 November 2017 Pages: 413 - 417

    

20. Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men

    • Richard Markus
    • Vincent Chow
    • Vladimir Hanes

    Correction Open access 20 November 2017 Pages: 419 - 419

21. Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)

    • Shang-Chiung Chen
    • Matts Kagedal
    • Chunze Li

    Correction 30 November 2017 Pages: 421 - 422

22. Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

    • Jan de Jong
    • Peter Hellemans
    • Daniele Ouellet

    Correction 06 December 2017 Pages: 423 - 423

23. Acknowledgement of reviewers 2016

    ACKNOWLEDGEMENT 03 January 2018 Pages: 425 - 425